Centanafadine · Simtriyo

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Attention Deficit Hyperactivity Disorder (label: Adults and pediatric patients 6 years and older weighing at least 20 kg)

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (10)
Attention Deficit Hyperactivity Disorder
NCT06926829 · Otsuka Pharmaceutical Co., Ltd.
2025-06-25 – 2027-12 · Attention Deficit Hyperactivity Disorder (ADHD)
What this study did
NCT07087327 · Otsuka Pharmaceutical Co., Ltd.
2025-09-16 – 2027-08 · Attention-Deficit Hyperactivity Disorder(ADHD)
What this study did
NCT07759154 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2026-09-01 – 2027-05-27 · Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
What this study did
NCT06973577 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2025-03-26 – 2026-04-29 · ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
What this study did
NCT05279313 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-02-24 – 2026-04-24 · Attention Deficit/Hyperactivity Disorder
What this study did
NCT03605849 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2019-02-14 – 2021-09-07 · Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
What this study did
Phase 2/3 (2)
Attention Deficit Hyperactivity Disorder
NCT06931080 · Otsuka Pharmaceutical Co., Ltd.
2025-04-30 – 2027-12 · Attention Deficit Hyperactivity Disorder (ADHD)
What this study did
NCT07086313 · Otsuka Pharmaceutical Co., Ltd.
2025-09-03 – 2027-08 · Attention-Deficit Hyperactivity Disorder(ADHD)
What this study did
Phase 2 (6)
Attention Deficit Hyperactivity Disorder
NCT04081363 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2019-10-07 – 2019-12-21 · Attention Deficit Hyperactivity Disorder
What this study did
NCT02547428 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2015-08-03 – 2016-06-04 · Attention Deficit Disorder With Hyperactivity
What this study did
NCT01939353 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2013-10-03 – 2014-02-20 · Adult ADHD
What this study did
Other / comorbidity
NCT05536414 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-09-12 – 2025-05-16 · Major Depressive Disorder
What this study did
NCT05113953 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2021-12-22 – 2022-08-19 · Binge-Eating Disorder
What this study did
NCT05066724 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2021-09-15 – 2022-05-31 · Smoking Cessation
What this study did
Phase 1 (9)
Attention Deficit Hyperactivity Disorder
NCT07314333 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2026-02-05 – 2026-04-15 · ADHD
What this study did
NCT04786730 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2021-03-09 – 2023-04-26 · Attention-deficit Hyperactivity Disorder
What this study did
NCT04398225 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2020-06-11 – 2021-04-01 · Attention Deficit Hyperactivity Disorder
What this study did
NCT02827513 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2015-12 – 2016-01 · Adult Attention-deficit Hyperactivity Disorder (ADHD)
What this study did
Other / comorbidity
NCT07253441 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2024-08-29 – 2024-12-30 · Attention Deficit Disorder With Hyperactivity
What this study did
NCT07486895 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2023-03-08 – 2023-05-18 · Healthy Adult Participants
What this study did
NCT07465731 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-10-27 – 2023-03-26 · Healthy Volunteers
What this study did
NCT02144415 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2014-05-01 – 2014-07-01 · Healthy Volunteers, Drug Users
What this study did
NCT01744808 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2013-02-01 – 2014-02-01 · Normal, Healthy Volunteers
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Attention Deficit Hyperactivity Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Centanafadine (Simtriyo): this drugApprovedSmall moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT05257265: ADHD-RS-5 change at week 6: -18.50 [0.93] centanafadine 328.8 mg vs -14.15 [0.93] placebo (p = .0006); 164.4 mg did not meet the primary endpoint
Viloxazine (Qelbree)ApprovedSmall moleculenorepinephrine transporterReliable signal
NCT04016779: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6): Placebo -11.7 units on a scale (Standard Error 0.9) | SPN-812 -15.5 units on a scale (Standard Error 0.91)
NCT03247543: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)): Placebo -11.7 units on a scale (Standard Error 1.48) | 200mg SPN-812 -17.6 units on a scale (Standard Error 1.43) | 400mg SPN-812 -17.5 units on a scale (Standard Error 1.52)
Ansofaxine Hydrochloride
Phase 3(overall)
Small moleculeSerotonin/norepinephrine/dopamine transporter
Reliable signal(overall)
No reviewed efficacy summary in this indication
Solriamfetol (Sunosi)Phase 3Small moleculeDopamine/norepinephrine transporternot yet gradedNo reviewed efficacy summary in this indication
Liafensine
Phase 2(overall)
Small moleculeSerotonin/norepinephrine/dopamine transporter
Reliable signal(overall)
No reviewed efficacy summary in this indication
Lysergide Tartrate (LSD) (DT120)Phase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
PDC-1421Phase 2BotanicalPolygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Simtriyo (Centanafadine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (5)
May 2027 (1)
Phase 3Attention Deficit Hyperactivity DisorderRecruiting
Est. primary completion 2027-05-27 · NCT07759154 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2/3Attention Deficit Hyperactivity DisorderRecruiting
Est. primary completion 2027-08 · NCT07086313 · CT.gov ↗
What to watch
Phase 3Attention Deficit Hyperactivity DisorderRecruiting
Est. primary completion 2027-08 · NCT07087327 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2/3Attention Deficit Hyperactivity DisorderRecruiting
Est. primary completion 2027-12 · NCT06931080 · CT.gov ↗
What to watch
Phase 3Attention Deficit Hyperactivity DisorderRecruiting
Est. primary completion 2027-12 · NCT06926829 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 July 2026ApprovalFDA Boxed Warning on Simtriyo (NDA218145)
US, FDA · FDA · Source ↗